MX2024007437A - Formulaciones estables de shr0302. - Google Patents
Formulaciones estables de shr0302.Info
- Publication number
- MX2024007437A MX2024007437A MX2024007437A MX2024007437A MX2024007437A MX 2024007437 A MX2024007437 A MX 2024007437A MX 2024007437 A MX2024007437 A MX 2024007437A MX 2024007437 A MX2024007437 A MX 2024007437A MX 2024007437 A MX2024007437 A MX 2024007437A
- Authority
- MX
- Mexico
- Prior art keywords
- shr0302
- exhibit
- pharmaceutical compositions
- api
- certain embodiments
- Prior art date
Links
- 229940126397 ivarmacitinib Drugs 0.000 title abstract 5
- 238000009472 formulation Methods 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 title abstract 2
- DNBCBAXDWNDRNO-FOSCPWQOSA-N (3aS,6aR)-N-(3-methoxy-1,2,4-thiadiazol-5-yl)-5-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]-3,3a,4,5,6,6a-hexahydro-1H-cyclopenta[c]pyrrole-2-carboxamide Chemical group COC1=NSC(NC(=O)N2C[C@H]3CC(C[C@H]3C2)N(C)C=2C=3C=CNC=3N=CN=2)=N1 DNBCBAXDWNDRNO-FOSCPWQOSA-N 0.000 abstract 4
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 abstract 4
- 230000015572 biosynthetic process Effects 0.000 abstract 2
- 239000013078 crystal Substances 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000013065 commercial product Substances 0.000 abstract 1
- 239000012049 topical pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/113—Multiple emulsions, e.g. oil-in-water-in-oil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163289780P | 2021-12-15 | 2021-12-15 | |
| US202263370740P | 2022-08-08 | 2022-08-08 | |
| PCT/US2022/081535 WO2023114832A1 (en) | 2021-12-15 | 2022-12-14 | Stable formulations of shr0302 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024007437A true MX2024007437A (es) | 2024-09-04 |
Family
ID=85018901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024007437A MX2024007437A (es) | 2021-12-15 | 2022-12-14 | Formulaciones estables de shr0302. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US12161643B2 (https=) |
| EP (1) | EP4447930A1 (https=) |
| JP (1) | JP2024544404A (https=) |
| KR (1) | KR20240125610A (https=) |
| AU (1) | AU2022413551A1 (https=) |
| CA (1) | CA3240662A1 (https=) |
| IL (1) | IL313482A (https=) |
| MX (1) | MX2024007437A (https=) |
| WO (1) | WO2023114832A1 (https=) |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3711602A (en) * | 1970-10-30 | 1973-01-16 | Crown Zellerbach Corp | Compositions for topical application for enhancing tissue penetration of physiologically active agents with dmso |
| US3934013A (en) | 1975-02-21 | 1976-01-20 | Syntex (U.S.A.) Inc. | Pharmaceutical composition |
| JP5732471B2 (ja) | 2009-12-22 | 2015-06-10 | レオ ファーマ アクティーゼルスカブ | 溶媒混合物およびビタミンｄ誘導体から成る医薬品組成物または類似体 |
| PT2796460T (pt) * | 2011-12-21 | 2018-11-05 | Shanghai hengrui pharmaceutical co ltd | Derivado pirrole de anel heteroarilo de seis membros, método de preparação do mesmo e suas utilizações médicas |
| PT3006445T (pt) | 2013-06-07 | 2018-01-09 | Jiangsu Hengrui Medicine Co | Bissulfato de inibidor de janus quinase (jak) e método de preparação para o mesmo |
| CN105566327A (zh) | 2014-10-09 | 2016-05-11 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的i型结晶及其制备方法 |
| WO2016070697A1 (zh) | 2014-11-05 | 2016-05-12 | 江苏恒瑞医药股份有限公司 | 一种jak激酶抑制剂的硫酸氢盐的结晶形式及其制备方法 |
| CA3014090A1 (en) | 2016-02-19 | 2017-08-24 | Jiangsu Hengrui Medicine Co., Ltd. | Pharmaceutical composition containing jak kinase inhibitor or pharmaceutically acceptable salt thereof |
| US20190060311A1 (en) | 2017-08-24 | 2019-02-28 | Aclaris Therapeutics, Inc. | Compositions and methods for treatment of vitiligo |
| SG11202001706RA (en) | 2017-10-27 | 2020-03-30 | Theravance Biopharma R&D Ip Llc | Pyrimidine compound as jak kinase inhibitor |
| WO2019096303A1 (zh) * | 2017-11-20 | 2019-05-23 | 江苏恒瑞医药股份有限公司 | 一种局部给药的药物组合物及其制备方法 |
| JP7268132B2 (ja) | 2018-07-31 | 2023-05-02 | エムシー２・セラピューティクス・リミテッド | 局所用組成物 |
| WO2020136650A1 (en) | 2018-12-25 | 2020-07-02 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an egfr inhibitor |
| WO2020236950A1 (en) | 2019-05-21 | 2020-11-26 | Dauntless 1, Inc. | Therapeutic microsphere formulations containing charged polymers |
| WO2022027041A1 (en) * | 2020-07-28 | 2022-02-03 | Arcutis Biotherapeutics, Inc. | Topical formulation containing jak inhibitor and laureth-4 |
| EP4237080A1 (en) | 2020-10-29 | 2023-09-06 | Arcutis Biotherapeutics, Inc. | Methods for treating vitiligo lesions having improved efficacy |
| MX2023005763A (es) * | 2020-11-17 | 2023-05-29 | Arcutis Biotherapeutics Inc | Composiciones y metodos para la administracion dermica profunda de farmacos. |
| CN114907353A (zh) * | 2021-02-09 | 2022-08-16 | 明慧医药（杭州）有限公司 | 一种前药化合物及其制备方法和用途 |
| CN114870016B (zh) | 2022-04-21 | 2023-05-26 | 上海博悦生物科技有限公司 | 一种jak抑制剂的微乳泡沫剂及其应用 |
-
2022
- 2022-12-14 CA CA3240662A patent/CA3240662A1/en active Pending
- 2022-12-14 EP EP22847098.5A patent/EP4447930A1/en active Pending
- 2022-12-14 IL IL313482A patent/IL313482A/en unknown
- 2022-12-14 WO PCT/US2022/081535 patent/WO2023114832A1/en not_active Ceased
- 2022-12-14 MX MX2024007437A patent/MX2024007437A/es unknown
- 2022-12-14 JP JP2024536283A patent/JP2024544404A/ja active Pending
- 2022-12-14 US US18/065,772 patent/US12161643B2/en active Active
- 2022-12-14 AU AU2022413551A patent/AU2022413551A1/en active Pending
- 2022-12-14 KR KR1020247023740A patent/KR20240125610A/ko active Pending
-
2024
- 2024-11-27 US US18/962,371 patent/US20250090535A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230181591A1 (en) | 2023-06-15 |
| AU2022413551A1 (en) | 2024-07-04 |
| CA3240662A1 (en) | 2023-06-22 |
| US20250090535A1 (en) | 2025-03-20 |
| EP4447930A1 (en) | 2024-10-23 |
| WO2023114832A9 (en) | 2023-10-05 |
| WO2023114832A1 (en) | 2023-06-22 |
| KR20240125610A (ko) | 2024-08-19 |
| JP2024544404A (ja) | 2024-11-29 |
| IL313482A (en) | 2024-08-01 |
| US12161643B2 (en) | 2024-12-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022007953A2 (es) | Heteroarilaminosulfonamidas de 5 miembros para tratar afecciones mediadas por una actividad deficiente de cftr | |
| PH12022550338A1 (en) | 2-hydroxycycloalkane-1-carbamoyl derivatives | |
| CL2019003228A1 (es) | Composiciones farmacéuticas de atropina. | |
| YU39800A (sh) | Derivati sulfonamida kao pro-lekovi inhibitora aspartil proteaze | |
| CL2020002252A1 (es) | Formulación oftálmica. | |
| SA522431777B1 (ar) | مشتقات ألفا -d- جالاكتو بيرانوسيد | |
| MX2023005039A (es) | Derivados de 2-hidroxicicloalcan-1-carbamoilo que inhiben la galectina-3. | |
| GEAP202415866A (en) | 3,6-diamino-pyridazin-3-yl derivatives, pharmaceutical compositions containing them and their uses as pro-apoptotic agents | |
| CO2020000168A2 (es) | Preparación sólida de cariprazina para administración oral | |
| CL2023003327A1 (es) | Inhibidores de la interaccion de menina-mll | |
| AR115303A1 (es) | Moduladores de calpaína y usos terapéuticos de los mismos | |
| MX2016008559A (es) | Composiciones de matriz polimerica que comprenden una alta concentracion de hialuronato de sodio bio-fermentado y usos de las mismas. | |
| AR130602A1 (es) | Inhibidores de tead y métodos de uso de los mismos | |
| TR200102008T2 (tr) | Serebral işemi profilaksı ve tedavisi için piridin türevlerinin kullanımı. | |
| EA201490363A1 (ru) | Новые составы на основе (триметоксифениламино)пиримидинилов | |
| MX2024007437A (es) | Formulaciones estables de shr0302. | |
| CO2021011042A2 (es) | Sales de sulcardina | |
| AR030376A1 (es) | Derivados aza-aminoacidos (inhibidores del factor xa-15) | |
| MX2022007176A (es) | 4-((2-oxopyri din-1 (2h)-yl)metil)benzamidas para el tratamiento de la deficiencia de alfa1-antitripsina. | |
| CN106551808A (zh) | 一种免洗洗手液 | |
| ES2059204T3 (es) | Derivados del acido hidroxamico inhibidores de lipoxigenasa. | |
| ECSP034713A (es) | Sales de adicion de acido malico de terbinafina | |
| ATE299027T1 (de) | Verwendung von übersulfatierten polysacchariden als hiv-hemmer | |
| MX2023011057A (es) | Derivados de indolina como inhibidores de receptores de dominio de discoidina 1 (ddr1) y receptores de dominio de discoidina 2 (ddr2). | |
| RU2008115908A (ru) | Фармацевтическая композиция, содержащая гиалуронидазу и липосомы для наружного применения |